{ "$schema_version": "5.4", "review_mode": "revision", "claim_restatement": { "index_wording": "Tumours are hierarchically organized around a rare self-renewing subpopulation that is necessary and sufficient to sustain and reinitiate the tumour.", "entry_form": "conjunction", "gradeable_restatement": "Across tumour types, a prospectively identifiable rare self-renewing cell subset occupies the apex of a functional hierarchy, is sufficient to serially reconstitute a heterogeneous tumour, and is necessary for tumour maintenance and post-treatment reinitiation because the remaining malignant cells cannot replace it.", "restatement_required": true, "split_into": [ "SC1", "SC2", "SC3", "SC4", "SC5", "SC6" ], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Across tumour types", "determinable_before_outcome": true, "determined_from": "Tumour histology and molecular subtype specified before the functional endpoint.", "action": "retained" }, { "qualifier": "prospectively identifiable rare self-renewing cell subset", "determinable_before_outcome": true, "determined_from": "A marker, lineage state, or functional state declared before tumour maintenance or recurrence is observed.", "action": "retained" }, { "qualifier": "the remaining malignant cells cannot replace it", "determinable_before_outcome": true, "determined_from": "Fate mapping and state-transition measurements specified before ablation or treatment.", "action": "retained" } ] }, "lay_summary": { "paragraphs": [ "The idea under review is that a tumour is run by a small group of special cells at the top of a one-way ladder: they renew themselves, they make all the other tumour cells, and only they can rebuild the cancer after treatment. If that were right, wiping out this small group should finish the disease.", "The sentence makes six promises at once, and they do not all hold. In some cancers and some stages, experiments in living animals do show that a particular stem-like group keeps the tumour growing or brings it back — that much is well established, and this review grades it Ε, context-specific causality established. But the promises made about all tumours fail: how rare these cells are turns out to depend on how you test for them, and when the group is destroyed, other tumour cells can change and take its place. So the hypothesis as written gets Γ, mechanistically plausible with partial system support. That is a verdict on the all-tumours version of the claim, not on the real biology of tumour-sustaining cells, which is solid and is better described by a flexible, changeable hierarchy than by a fixed ladder." ], "grade_restated_faithfully": true, "claims_referenced": [ "C1", "C3", "C4", "C6", "C7", "C9", "C10", "C11", "C12" ], "jargon_glossed": true, "no_practical_advice": true, "written_for": "Readers without cancer-biology training" }, "hypothesis": { "name": "Rare, fixed cancer stem cell hierarchy", "central_claim": "Tumours are hierarchically organized around a rare self-renewing subpopulation that is necessary and sufficient for maintenance and reinitiation.", "proposed_mechanism": "A discrete apex population self-renews and produces more differentiated malignant progeny, while those progeny lack durable tumour-sustaining capacity and cannot replenish the apex population.", "claimed_scope": "Tumour types generally, spanning initiation, maintenance, and relapse.", "claimed_level": [ "initiation", "maintenance", "propagation", "response" ], "is_conjunctive": true, "conjunctive_note": "Rarity, hierarchy, sufficiency, maintenance necessity, relapse necessity, and irreplaceability are separate burdens; no single experiment establishes all of them across cancers." }, "rubric_routing": { "primary_rubric": "02-cancer-biology.md", "secondary_rubrics": [], "index_notes_applied": [ "Score existence, maintenance necessity, relapse necessity, and stability/plasticity separately.", "Score by tumour type; evidence is strongest in AML and weaker or different in many solid tumours.", "Xenograft tumour initiation without lineage-resolved endogenous evidence is capped at Γ.", "Plasticity evidence directly tests the fixed-hierarchy clause.", "Use scope-matched aggregation and report aggregation alternatives." ], "rubric_fit_note": "Direct fit. The packet supplies the adjudication method; the user-supplied biological proposition is the assessed claim.", "routing_check_performed": "All seven evidence rubrics were examined in the red-team pass (finding RT-15). Rubric 02 scopes \"stemness ... and hierarchical organization\" and names the cancer stem cell hypothesis as its first example: a direct fit. Rubrics 01, 04, 06 and 07 are out of scope. Rubric 03 (chromatin/nuclear organization) and rubric 05 (immune-centred models) are arguable but do not apply: the chromatin evidence (YAP/AP-1 oncofetal reprogramming, centromeric accessibility in EMT) and the immune evidence (T-cell exclusion in residual micrometastases) support the rival model rather than the nominal claim, and routing follows the claim being graded. No cross-field lowest-ceiling rule binds; had rubric 03 applied, its Γ cap is not lower than the level assigned here." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "A functional self-renewal and differentiation hierarchy exists in tumours.", "subclaim_type": "existence", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "Tumour types generally, with tumour-type-specific findings retained.", "scope": "Endogenous or disease-relevant tumour growth; transplantation findings are reported separately.", "key_evidence_anchor": "Durable lineage-resolved self-renewal and differentiated progeny in native tumours.", "hsef_level": "Ε", "confidence": "High", "governing_cap_or_threshold": "Ε requires context-specific causal validity with mapped limits.", "rationale": "Native lineage tracing establishes functional hierarchy in mouse papilloma and intestinal adenoma, while invasive squamous cancer and melanoma show different architectures. The mapped failures of generalization make Ε appropriate." }, { "id": "SC2", "statement": "Tumour-sustaining capacity is confined to a rare subpopulation.", "subclaim_type": "generalization", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "Tumour types generally.", "scope": "Prospectively sampled viable malignant cells in a stated host and niche, with rarity defined before outcome.", "key_evidence_anchor": "Endogenous single-cell fate mapping and depletion demonstrating a consistently rare, exclusive sustaining compartment across tumour contexts.", "hsef_level": "Γ", "confidence": "High", "governing_cap_or_threshold": "Xenograft initiation alone is Γ-capped, and permissive melanoma assays directly weaken rarity.", "rationale": "Rarity is strong in selected AML and breast transplantation systems but is assay-dependent; permissive melanoma transplantation found tumour-forming capacity in a substantial fraction of cells." }, { "id": "SC3", "statement": "The prospectively identified rare subset is sufficient by itself to serially reconstitute a heterogeneous tumour.", "subclaim_type": "sufficiency", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "Tumour types generally.", "scope": "Serial tumour reconstitution in a disease-relevant permissive setting; spontaneous relapse in the original host is not inferred from transplantation.", "key_evidence_anchor": "Prospective single-cell or clonal transplantation plus matched endogenous lineage confirmation across tumour types.", "hsef_level": "Γ", "confidence": "High", "governing_cap_or_threshold": "Serial xenograft initiation without lineage-resolved endogenous confirmation is capped at Γ for the broad claim.", "rationale": "AML and breast studies establish transplantation sufficiency for selected populations, but host permissiveness changes measured frequency and the result does not establish universal endogenous sufficiency." }, { "id": "SC4", "statement": "Eliminating the proposed stem-like population prevents continued tumour maintenance.", "subclaim_type": "necessity", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "Established tumours across tumour types.", "scope": "Endogenous or disease-relevant established tumours, with direct cell-state ablation and tumour-growth endpoints.", "key_evidence_anchor": "Selective ablation in autochthonous tumours, with matched state tracking and a hard growth or survival endpoint.", "hsef_level": "Ε", "confidence": "High", "governing_cap_or_threshold": "Endogenous ablation crosses Δ; heterogeneous bypass and tissue-stage boundaries map the claim to Ε.", "rationale": "Autochthonous glioma and lung studies show causal maintenance contributions in defined settings (Chen 2012; Chan 2026). Primary colorectal tumours can persist or regrow after single-state depletion, preventing a universal necessity claim. Mzoughi 2025 is supporting evidence at transplanted-organoid rather than autochthonous depth." }, { "id": "SC5", "statement": "Eliminating the proposed stem-like population prevents post-treatment tumour reinitiation or relapse.", "subclaim_type": "necessity", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "Post-treatment recurrence across tumour types.", "scope": "Relapse or renewed growth in the original disease-relevant host after therapy or surgery; serial transplantation alone is excluded.", "key_evidence_anchor": "Pre-treatment or residual-state ablation followed through recurrence, with lineage tracking of escape.", "hsef_level": "Ε", "confidence": "High", "governing_cap_or_threshold": "Relapse-specific functional tests cross Δ; stage-specific dependencies and alternative relapse origins map the boundary to Ε.", "rationale": "Quiescent glioma and EMP1-high colorectal residual cells causally contribute to regrowth, but LGR5 ablation did not prevent colorectal relapse and human AML relapses can arise through more than one cellular route." }, { "id": "SC6", "statement": "Cells outside the proposed subset cannot replenish an equivalent tumour-sustaining population sufficiently to bypass its elimination.", "subclaim_type": "mechanism", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "Physiological and treatment settings across tumour types.", "scope": "Lineage-resolved state transitions after selective depletion in native or disease-relevant tumours.", "key_evidence_anchor": "Long-term depletion with fate mapping showing no functional re-entry from non-stem states under physiological and treatment pressure.", "hsef_level": "Γ", "confidence": "High", "governing_cap_or_threshold": "Direct replenishment and reversible-state evidence falsify exclusivity; the remaining positive basis is partial-system plausibility.", "rationale": "Differentiated or LGR5-negative colorectal cells, and cells outside the lung high-plasticity state, can regenerate tumour-sustaining function; Jiang 2026 identifies a regulated dedifferentiation switch for that route. This is a direct failure of the fixed irreplaceable-compartment clause. Chan 2026 demonstrates acquisition of the state in orthotopic transplantation and serial allograft, not replenishment after in-situ ablation, where the authors attribute residual cells to incomplete recombination." } ], "aggregation_rule": "scope-matched", "aggregation_preregistered": true, "aggregation_rationale": "The hypothesis index prescribes scope-matched aggregation for this entry. Its stated rationale is that \"the universal CSC framing is scored by the strength of the evidence in the weakest tumor context claimed, while specific tumor-type subclaims are reported separately\".", "primary_subclaim_id": "SC4", "aggregation_derivation": "Scope-matched sets the overall level to the highest subclaim whose scope matches the central claim's scope (SKILL.md Step 3). The central claim is stated across tumour types and is conjunctive. The subclaims at that scope are SC2, SC3 and SC6, all Γ, so the overall is Γ. SC1, SC4 and SC5 reach Ε only within defined tumour contexts; because Ε is defined as context-specific causality whose generalization to the full claimed scope fails, an Ε subclaim cannot be the subclaim whose scope matches a universally scoped claim, and the rule directs that such narrower subclaims be reported separately.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Ε", "scope_matched_would_return": "Γ", "note": "The prescribed rule (scope-matched) and weakest-link agree at Γ. Only primary-subclaim aggregation on SC4, which was not the prescribed rule, returns Ε. The spread is one rung and is driven entirely by rule choice on identical evidence, which is why the rule is pre-registered and the arithmetic shown. The two-rung visibility rule is not triggered." }, "index_rule_deviation": "No deviation. The index's prescribed scope-matched rule and its instruction to judge the universal framing in the weakest tumour context claimed are both applied, and they agree on Γ. The prior edition of this card recorded the rule as \"retained\" while representing the weakest-tumour-context instruction as a mere alternative and keeping Ε as the headline; that was a deviation presented as compliance, and it is corrected here (finding RT-01)." }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M4", "is_nominal": false, "name": "Context-dependent dynamic hierarchy with plasticity and clonal selection", "core_claim": "Tumour-sustaining states are causal in defined cancers and stages, but their frequency, identity, and accessibility change with genotype, niche, therapy, and reversible state transitions.", "explains_what_nominal_does_not": "Explains strong lineage and ablation results together with assay-dependent frequency, single-state bypass, non-stem-to-stem conversion, and distinct relapse routes.", "strongest_supporting_evidence": [ "[5]", "[7]", "[8]", "[9]", "[11]", "[12]", "[13]", "[14]" ], "strongest_contradictory_evidence": [ "[1]", "[2]", "[6]" ], "hsef_level_for_this_model": "Ζ", "rationale": "Endogenous lineage tracing, direct ablation, patient-derived systems, and state-transition studies converge through different failure modes. They preserve context-specific hierarchy while making a fixed universal apex unnecessary." }, { "rank_in_tournament": 2, "model_id": "M3", "is_nominal": false, "name": "Clonal evolution with selected stem-like phenotypes", "core_claim": "Genetic and epigenetic clonal selection generates variable self-renewal capacity, and stem-like behavior reflects selected clones rather than a universal cellular hierarchy.", "explains_what_nominal_does_not": "Explains genetically distinct relapse routes and changes under treatment pressure.", "strongest_supporting_evidence": [ "[10]", "[12]", "[13]", "[14]" ], "strongest_contradictory_evidence": [ "[5]", "[6]", "[7]" ], "hsef_level_for_this_model": "Ε", "rationale": "Clonal selection is well supported, but it does not by itself explain reproducible state-specific maintenance dependencies or differentiation hierarchies." }, { "rank_in_tournament": 3, "model_id": "M1", "is_nominal": true, "name": "Rare fixed cancer stem cell hierarchy", "core_claim": "A rare, discrete, self-renewing apex population is uniquely sufficient and necessary for tumour maintenance and relapse.", "explains_what_nominal_does_not": "Provides a simple unifying explanation for tumour heterogeneity, serial transplantation, persistence, and recurrence.", "strongest_supporting_evidence": [ "[1]", "[2]", "[6]", "[7]", "[10]", "[15]" ], "strongest_contradictory_evidence": [ "[3]", "[4]", "[5]", "[8]", "[9]", "[11]", "[12]", "[13]", "[14]" ], "hsef_level_for_this_model": "Ε", "rationale": "Context-specific causal dependencies are established, but rarity, stability, exclusivity, and cross-tumour necessity are not. The nominal model survives only after being narrowed to contexts where it no longer makes the universal fixed-compartment claim.", "level_note": "The nominal model carries the same letter as the overall assessment, Γ, for the same reason: its universal rare, stable, exclusive compartment is the part that fails." }, { "rank_in_tournament": 4, "model_id": "M2", "is_nominal": false, "name": "Stochastic equipotence", "core_claim": "Most malignant cells have comparable long-term tumour-sustaining potential, with observed differences arising mainly from stochastic events and assay conditions.", "explains_what_nominal_does_not": "Explains the high melanoma tumour-forming frequency under permissive transplantation.", "strongest_supporting_evidence": [ "[3]", "[4]" ], "strongest_contradictory_evidence": [ "[5]", "[6]", "[7]", "[12]", "[14]" ], "hsef_level_for_this_model": "Ε", "rationale": "Equipotence fits selected melanoma and invasive squamous-cancer observations but fails where durable lineage asymmetry and cell-state-specific ablation effects are directly demonstrated." } ], "tournament_summary": "The shared evidence favors a context-dependent dynamic hierarchy in which tumour-sustaining states matter causally but are not uniformly rare, fixed, or irreplaceable. The nominal rare fixed hierarchy explains selected serial-transplantation and ablation results and fails as a universal compartment. The ranking reflects explanatory fit across the shared evidence and informs the role of mechanism only.", "study_separating_rank1_from_rank2": "Cañellas-Socias et al. 2022 most sharply separates the dynamic-hierarchy model from clone-only selection by prospectively identifying and ablating an EMP1-high residual state that seeds colorectal recurrence while showing that preoperative LGR5-cell ablation does not prevent relapse.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "citation": "Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine. 1997.", "source_pointer": "PMID:9212098; DOI:10.1038/nm0797-730", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "Human AML cells transplanted into immunodeficient mice", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A prospectively enriched primitive AML fraction initiated leukaemia and reproduced phenotypic hierarchy in xenografts.", "what_it_does_not_show": "It does not establish necessity in the patient or generalize rarity and stability to solid tumours.", "confounders_present": [ "xenograft host", "engraftment selection", "marker dependence" ], "verification": "verified", "verification_note": "PubMed abstract and metadata checked against the primary record.", "source_tier": "A" }, { "citation": "Al-Hajj M et al. Prospective identification of tumorigenic breast cancer cells. PNAS. 2003.", "source_pointer": "PMID:12629218; DOI:10.1073/pnas.0530291100", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "Human breast-cancer xenografts", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A selected CD44-positive, CD24-negative/low fraction formed serially transplantable heterogeneous tumours at far lower cell doses than comparator fractions.", "what_it_does_not_show": "It does not prove a fixed endogenous breast-cancer hierarchy or exclude host- and assay-dependent detection.", "confounders_present": [ "xenograft artifact", "surface-marker instability", "recipient permissiveness" ], "verification": "verified", "verification_note": "Complete accessible primary full text checked; attached author correction recorded in the ledger.", "source_tier": "A" }, { "citation": "Quintana E et al. Efficient tumour formation by single human melanoma cells. Nature. 2008; and Quintana E et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010.", "source_pointer": "PMID:19052619; DOI:10.1038/nature07567; PMID:21075313; DOI:10.1016/j.ccr.2010.10.012", "relates_to_subclaims": [ "SC2", "SC3", "SC6" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Moderate", "system": "Human melanoma cells in highly permissive xenograft assays", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Tumour-forming frequency increased markedly under permissive conditions, many single melanoma cells formed tumours, and tested markers did not isolate a large stable non-tumorigenic fraction.", "what_it_does_not_show": "It does not prove equipotence in untreated human melanoma in situ.", "confounders_present": [ "xenograft assay", "Matrigel", "recipient immune deficiency", "single-laboratory program" ], "verification": "verified", "verification_note": "Complete accessible primary full texts checked for assay conditions, tumour frequency, and marker reversibility.", "source_tier": "A" }, { "citation": "Driessens G et al. Defining the mode of tumour growth by clonal analysis. Nature. 2012.", "source_pointer": "PMID:22854777; DOI:10.1038/nature11344", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Strong", "system": "Endogenous mouse skin papilloma and squamous carcinoma lineage tracing", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Papillomas displayed a persistent stem-like proliferative compartment and transient progenitors, while invasive squamous cancers were compatible with a single equipotent proliferative population.", "what_it_does_not_show": "Lineage tracing alone does not prove that the persistent compartment is necessary, and the invasive result limits generalization.", "confounders_present": [ "mouse tumour model", "lineage-label sampling", "stage dependence" ], "verification": "verified", "verification_note": "Complete primary PDF checked, including the model-estimated division rates that correct an error in the prior review.", "source_tier": "A" }, { "citation": "Schepers AG et al. Lineage tracing reveals Lgr5-positive stem cell activity in mouse intestinal adenomas. Science. 2012.", "source_pointer": "PMID:22855427; DOI:10.1126/science.1224676", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "Endogenous mouse intestinal adenoma lineage tracing", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A minority Lgr5-positive adenoma population produced long-lived multilineage clones in native tumours.", "what_it_does_not_show": "It does not test ablation, relapse necessity, or irreversible hierarchy.", "confounders_present": [ "mouse adenoma", "marker-defined state", "no necessity test" ], "verification": "verified", "verification_note": "Complete primary PDF checked for lineage design, frequency, and interpretation.", "source_tier": "A" }, { "citation": "Chen J et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012.", "source_pointer": "PMID:22854781; DOI:10.1038/nature11287", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "Endogenous mouse glioma lineage tracing and genetic ablation", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A quiescent Nestin-expressing population regenerated gliomas after temozolomide, and its ganciclovir-mediated ablation impaired growth and prolonged survival.", "what_it_does_not_show": "New tumours arising where the ablation transgene was silent and model specificity prevent universal necessity or cure claims.", "confounders_present": [ "engineered mouse model", "transgene-silencing escape", "marker-state specificity" ], "verification": "verified", "verification_note": "Complete accessible primary full text checked for lineage, ablation, chemotherapy, survival, and escape results.", "source_tier": "A" }, { "citation": "de Sousa e Melo F et al. A distinct role for Lgr5-positive stem cells in primary and metastatic colon cancer. Nature. 2017; and Shimokawa M et al. Visualization and targeting of LGR5-positive human colon cancer stem cells. Nature. 2017.", "source_pointer": "PMID:28358093; DOI:10.1038/nature21713; PMID:28355176; DOI:10.1038/nature22081", "relates_to_subclaims": [ "SC4", "SC5", "SC6" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "Mouse colorectal tumours and transplanted human colorectal organoids", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Lgr5-cell ablation restricted primary growth without durable regression, while Lgr5-negative or differentiated cells replenished Lgr5-positive tumour-propagating cells; metastatic dependence differed from primary-tumour dependence.", "what_it_does_not_show": "The paired evidence does not establish that every colorectal tumour uses the same states or transition rates.", "confounders_present": [ "marker-specific ablation", "mouse-human system differences", "transplantation in the organoid study" ], "verification": "verified", "verification_note": "Primary abstracts and accessible publisher summaries checked; exact effect sizes were not used.", "source_tier": "A" }, { "citation": "Shlush LI et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017.", "source_pointer": "PMID:28658204; DOI:10.1038/nature22993", "relates_to_subclaims": [ "SC5", "SC6" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Strong", "system": "Paired human AML diagnosis-relapse samples with functional and genomic tracking", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Human AML relapse arose through at least two cellular patterns, including rare stem/progenitor cells and larger committed populations with stemness programs.", "what_it_does_not_show": "It is not a direct ablation test and does not establish that either origin is universally necessary.", "confounders_present": [ "observational human relapse tracking", "sampling depth", "therapy selection" ], "verification": "verified", "verification_note": "PubMed abstract and metadata checked against the primary record.", "source_tier": "A" }, { "citation": "Fumagalli A et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell. 2020.", "source_pointer": "PMID:32169167; DOI:10.1016/j.stem.2020.02.008", "relates_to_subclaims": [ "SC4", "SC5", "SC6" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "Lineage-resolved mouse colorectal metastasis models", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Lgr5-negative disseminated cells seeded metastases, acquired Lgr5 expression, and re-established a hierarchy; the Lgr5 state then supported long-term outgrowth.", "what_it_does_not_show": "It does not make the Lgr5 state irrelevant; it separates seeding competence from later outgrowth dependence.", "confounders_present": [ "mouse colorectal models", "marker-state dynamics", "metastatic niche" ], "verification": "verified", "verification_note": "Complete primary full text checked for dissemination, state conversion, and outgrowth experiments.", "source_tier": "A" }, { "citation": "Cañellas-Socias A et al. Metastatic recurrence in colorectal cancer arises from residual EMP1-positive cells. Nature. 2022.", "source_pointer": "PMID:36352230; DOI:10.1038/s41586-022-05402-9", "relates_to_subclaims": [ "SC4", "SC5", "SC6" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "Mouse colorectal surgical-recurrence models with lineage tracing and ablation", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "EMP1-high residual cells seeded recurrence and preoperative ablation prevented most relapses, whereas preoperative Lgr5-cell ablation did not; isolated tumour states could re-establish heterogeneity.", "what_it_does_not_show": "EMP1-high cells were not shown to be a universal fixed apex population, and ablation after dissemination had different effects.", "confounders_present": [ "mouse recurrence model", "stage-specific intervention timing", "state-marker specificity" ], "verification": "verified", "verification_note": "Complete primary full text and methods checked for recurrence, ablation timing, Lgr5 comparison, and state plasticity.", "source_tier": "A" }, { "citation": "Mzoughi S et al. Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Nature Genetics. 2025.", "source_pointer": "PMID:39930084; DOI:10.1038/s41588-024-02058-1", "relates_to_subclaims": [ "SC4", "SC6" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "transplanted organoid (subcutaneous allograft, NSG)", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "LGR5-positive and oncofetal states formed a plastic continuum; sustained depletion of either state alone was bypassed, while co-depletion produced regression during treatment.", "what_it_does_not_show": "It does not prove that every colorectal tumour has the same two-state architecture or that co-depletion is durably curative after withdrawal.", "confounders_present": [ "WNT-dependent colorectal scope", "state-target specificity", "treatment-duration dependence" ], "verification": "verified", "verification_note": "Complete primary full text and methods checked for single-state and combined depletion results.", "source_tier": "A", "endogenous_note": "Depletion experiments used VAKSP tumoroids injected subcutaneously into both flanks of NSG mice — a heterotopic allograft of engineered organoids, not an autochthonous tumour (finding RT-04)." }, { "citation": "Chan JE et al. Critical role for a high-plasticity cell state in lung cancer. Nature. 2026.", "source_pointer": "PMID:41565826; DOI:10.1038/s41586-025-09985-x", "relates_to_subclaims": [ "SC1", "SC4", "SC5", "SC6" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "Autochthonous mouse lung cancer with in situ lineage tracing and ablation", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A high-plasticity state contributed to progression, maintenance, and treatment resistance; its ablation suppressed these endpoints, while other tumour cells could enter the state.", "what_it_does_not_show": "It does not support a one-way apex hierarchy; the authors' data support a transition hub that can be reacquired.", "confounders_present": [ "mouse lung models", "state-definition transfer to humans", "incomplete state ablation" ], "verification": "verified", "verification_note": "Complete primary full text and methods checked for lineage tracing, ablation, reacquisition, and treatment effects.", "source_tier": "A" }, { "citation": "Ohta Y et al. Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022.", "source_pointer": "PMID:35798028; DOI:10.1038/s41586-022-05043-y", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "Human colorectal organoid xenografts under chemotherapy", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Dormant LGR5-positive cells persisted through chemotherapy and later expanded; COL17A1 disruption reduced the dormant fraction and increased treatment sensitivity.", "what_it_does_not_show": "The xenograft setting does not establish universal human relapse necessity or a fixed, irreplaceable compartment.", "confounders_present": [ "organoid xenograft", "treatment-selected dormancy", "matrix dependence" ], "verification": "verified", "verification_note": "PubMed abstract and metadata checked against the primary record; no exact effect size used.", "source_tier": "A" }, { "citation": "Shah MA et al. CanStem303C phase III, napabucasin plus FOLFIRI in metastatic colorectal cancer. Clin Colorectal Cancer. 2023.", "source_pointer": "PMID:36503738; DOI:10.1016/j.clcc.2022.11.002", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M2", "M4" ], "direction": "contradicts", "decisive_perturbation": false, "endogenous": false, "note": "Human therapeutic perturbation with a hard endpoint; null. Agent's CSC-directedness is contested, so it constrains the targetable-rare-compartment corollary rather than falsifying stem-cell necessity.", "added_by": "red-team synthesis 2026-09-30", "source_tier": "A", "evidence_class": "human randomized controlled trial, phase III", "system": "previously treated metastatic colorectal cancer, n=1,253", "what_it_shows": "Adding napabucasin to FOLFIRI did not improve overall survival (14.3 vs 13.8 months, HR 0.976, one-sided P=.74; pSTAT3-positive 13.2 vs 12.1 months, HR 0.969, one-sided P>.99). The only large human therapeutic test of a putative CSC-directed agent with a hard endpoint is null.", "what_it_does_not_show": "It does not falsify stem-cell necessity. Napabucasin is a reactive-oxygen-species generator bioactivated by NQO1 whose CSC-directedness is contested, and no on-treatment depletion of a declared cell state was demonstrated in patients.", "confounders_present": "Agent mechanism uncertain; open-label; pSTAT3 is an adverse prognostic factor, which complicates the biomarker-positive comparison.", "verification": "verified" }, { "citation": "Cortes JE et al. Glasdegib plus low-dose cytarabine versus low-dose cytarabine in AML/high-risk MDS, randomized phase II. Leukemia. 2019.", "source_pointer": "PMID:30555165; DOI:10.1038/s41375-018-0312-9", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1", "M4" ], "direction": "supports", "decisive_perturbation": false, "endogenous": false, "note": "Human therapeutic perturbation with a hard endpoint; positive, in the tumour type where hierarchy evidence is strongest. Hedgehog inhibition is pleiotropic and no population-selective killing was demonstrated.", "added_by": "red-team synthesis 2026-09-30", "source_tier": "A", "evidence_class": "human randomized controlled trial, phase II", "system": "newly diagnosed AML or high-risk MDS unsuitable for intensive chemotherapy, n=88 vs 44", "what_it_shows": "Glasdegib plus low-dose cytarabine improved median overall survival (8.8 months, 80% CI 6.9-9.9, vs 4.9 months, 3.5-6.0; HR 0.51, 80% CI 0.39-0.67, P=0.0004) with complete remission in 17.0% vs 2.3%, in the tumour type where hierarchy evidence is strongest.", "what_it_does_not_show": "It does not show population-selective killing of a rare compartment. Hedgehog inhibition is pleiotropic, and survival benefit is compatible with mechanisms other than elimination of a stem-cell apex.", "confounders_present": "Pathway pleiotropy; phase II with 80% confidence intervals; open-label; unfit-patient population limits generalization.", "verification": "verified" }, { "citation": "Jiang Q et al. ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer. Nature. 2026.", "source_pointer": "PMID:42557330; DOI:10.1038/s41586-026-10890-0", "relates_to_subclaims": [ "SC6" ], "favors_models": [ "M1", "M4" ], "direction": "contradicts", "decisive_perturbation": true, "endogenous": true, "note": "Gives the dedifferentiation route a regulated molecular switch; endogenous mouse colon regeneration plus human CRC loss-of-function.", "added_by": "red-team synthesis 2026-09-30", "source_tier": "A", "evidence_class": "endogenous genetic perturbation plus human tumour loss-of-function", "system": "mouse colon regeneration models; human colorectal cancer models", "what_it_shows": "ZFP36L2 is a stress-responsive switch for dynamic dedifferentiation: its ablation inhibits dedifferentiation, intestinal-stem-cell gene expression and function, and impairs regeneration; loss of function in human CRC abrogates metastatic seeding and outgrowth of LGR5-positive canonical metastases while promoting non-canonical lineage plasticity. Gives the replenishment route a regulated molecular basis.", "what_it_does_not_show": "It does not establish that dedifferentiation is the only route to tumour-sustaining function, nor that blocking it is durable; the regeneration arm is not a tumour maintenance experiment.", "confounders_present": "Regeneration and tumour contexts are distinct; human arm relies on engineered loss of function rather than native variation.", "verification": "verified" }, { "citation": "Perelli L et al. Evolutionary fingerprints of epithelial-to-mesenchymal transition. Nature. 2025.", "source_pointer": "PMID:40044861; DOI:10.1038/s41586-025-08671-2", "relates_to_subclaims": [ "SC1", "SC6" ], "favors_models": [ "M1", "M2" ], "direction": "supports", "decisive_perturbation": true, "endogenous": true, "note": "Somatic mosaic trace-and-ablate of a plastic state in pancreatic cancer; supports cell-state-restricted evolution rather than a fixed apex compartment.", "added_by": "red-team synthesis 2026-09-30", "source_tier": "A", "evidence_class": "somatic mosaic genome engineering, trace-and-ablate", "system": "autochthonous mouse pancreatic cancer, with cross-species human comparison", "what_it_shows": "Tracing and ablating malignant mesenchymal lineages along the EMT continuum abolished the associated mutational processes and evolutionary patterns, supporting cell-state-restricted patterns of evolution and extending state-specific trace-and-ablate to a further tumour type.", "what_it_does_not_show": "The mesenchymal state is not the nominal rare apex compartment, and the study does not test rarity, prospective marker identity, or irreplaceability of a declared stem population.", "confounders_present": "State definition is continuum-based rather than marker-discrete; ablation coverage and clone-size effects are engineering-dependent.", "verification": "verified" } ], "verification_summary": { "load_bearing_claims_checked": 17, "verified": 17, "unverified": 0, "contradicted": 0, "note": "All 17 registered load-bearing claims were checked against primary records in the red-team pass. Nine sources were read at complete-full-text depth and ten at abstract/metadata depth. All 19 identifiers (PMID, DOI, PMCID) resolve to the claimed paper on title, first author, journal and year; no retractions or expressions of concern were found. One numeric claim (C2) was restated because its reported figures were unverifiable; five further claims were made more precise. The Al-Hajj author correction is attached to its parent ledger row as a status flag rather than given its own numbered row." }, "factual_issues_found": [ { "quoted_text": "The vast majority of labelled tumour cells had only limited proliferative potential, representing a transient population that cycled rapidly (twice per day)", "problem": "The prior review assigns the approximately twice-daily division rate to the transient progenitor population.", "source_says": "Driessens et al. assign the approximately twice-daily division rate to the persistent stem-like proliferative population; the committed progenitor pool was modelled at approximately 0.5 divisions per day.", "source_pointer": "PMID:22854777; DOI:10.1038/nature11344", "affects_score": false, "action": "scored-on-corrected-understanding" }, { "quoted_text": "in one experiment, 200 CD44-positive, CD24-negative/low cells formed tumours whereas 20,000 comparator cells did not", "problem": "Neither figure appears in any record reachable with available tools; the abstract reports as few as 100 cells versus tens of thousands, in eight of nine patients.", "resolution": "Replaced with the abstract-verified figures; ledger access depth corrected to abstract_metadata.", "finding_id": "RT-03" }, { "quoted_text": "Endogenous genetic manipulation in autochthonous models ... Mzoughi et al. 2025 [13]", "problem": "Mzoughi's depletion experiments were subcutaneous flank allografts of VAKSP tumoroids in NSG mice, not autochthonous tumours.", "resolution": "Reclassified as a transplanted-organoid perturbation; endogenous flag set false; endogenous decisive-perturbation tally 8 -> 7. SC4 level unchanged, carried by Chen 2012 and Chan 2026.", "finding_id": "RT-04" }, { "quoted_text": "Ablation suppressed those endpoints, but other tumour cells could enter the state [14]", "problem": "Chan et al. demonstrate non-HPCS-to-HPCS acquisition by orthotopic transplantation and serial allograft, not by replenishment after in-situ ablation; the residual cells in the ablation experiment are attributed by the authors to incomplete recombination, and they state their results probably underestimate the importance of the state.", "resolution": "Description corrected and the authors' caveat and clonal-line control added. SC6 level unchanged, carried independently by de Sousa e Melo 2017, Shimokawa 2017, Fumagalli 2020 and Mzoughi 2025.", "finding_id": "RT-05" }, { "quoted_text": "depletion of both caused regression while treatment continued", "problem": "The paper reports tumour shrinkage and significantly delayed resurgence; resurgence occurred.", "resolution": "Wording tightened to the paper's.", "finding_id": "RT-08" }, { "quoted_text": "The estimated tumour-forming fraction rose to approximately 25%; in one single-cell series, 69 of 254 injections formed tumours", "problem": "Two separate experiments were run together: ~25% is the limiting-dilution estimate across 12 patients, while 69/254 (27%) is the pooled single-cell result across four patients, ranging 12-65% per patient.", "resolution": "Each figure attributed to its own experiment, with the per-patient range added.", "finding_id": "RT-09" }, { "quoted_text": "roughly 0.5 divisions per day to committed progenitors", "problem": "The paper states the stem-like rate (twice per day) and the ratio (approximately four times the progenitor rate); 0.5 per day is the reviewer's arithmetic, presented as reported.", "resolution": "Retained but marked as derived from the paper's stated four-fold ratio.", "finding_id": "RT-10" } ], "cap_rules_applied": [ { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Xenograft tumor-initiation without lineage-resolved endogenous evidence", "specific_trigger": "The strongest evidence for a rare initiating fraction in AML and breast cancer is xenograft-based, while a permissive melanoma assay materially changes the estimated frequency.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Xenograft tumor-initiation without lineage-resolved endogenous evidence", "specific_trigger": "Serial reconstitution in the classic AML and breast studies tests transplantation sufficiency, not broad endogenous sufficiency or relapse in the original host.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC6", "cap": "Γ", "cap_source": "boundary check", "triggered": true, "trigger_text_quoted": "A negative field-valid perturbation does not cross Δ", "specific_trigger": "Direct depletion and lineage experiments show robust reacquisition of tumour-sustaining states, so the exclusive, irreplaceable-compartment prediction fails.", "resulting_ceiling": "Γ", "note": "Carried independently by de Sousa e Melo 2017, Shimokawa 2017, Fumagalli 2020 and Mzoughi 2025; Chan 2026 contributes transplantation-based acquisition evidence only (finding RT-05)." } ], "cap_precedence_resolutions": [ { "collision": "The cancer rubric recognizes endogenous lineage or ablation as threshold-crossing, while the transplantation hard rule caps xenograft inference at Γ.", "subclaim_scope_cap_binds_on": "SC2 and SC3 at their cross-tumour rarity and sufficiency scope.", "subclaim_scope_threshold_binds_on": "SC1, SC4, and SC5 within native mouse tumour or disease-relevant recurrence systems.", "resolution": "Endogenous lineage and ablation cross the causal threshold within the systems tested; the Γ cap continues to govern inference from xenograft initiation to the broad rare-and-sufficient claim.", "note": "The evidence classes are separated rather than averaged." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Endogenous lineage tracing in vivo", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Driessens et al. 2012 [5]; Schepers et al. 2012 [6]", "gamma_hard_rules_triggered": [], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Native lineage tracing shows durable self-renewal and differentiated progeny in specified tumour contexts.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "Endogenous lineage tracing in vivo", "qualifying_evidence_present": "unclear", "qualifying_evidence_citation": "Classic rarity estimates come from Bonnet and Dick 1997 [1] and Al-Hajj et al. 2003 [2]; Quintana et al. [3,4] show assay dependence.", "gamma_hard_rules_triggered": [ "Xenograft tumor-initiation without lineage-resolved endogenous evidence" ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Endogenous studies support minority states in some tumours but do not establish universally rare and exclusive sustaining capacity.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "Patient-derived system perturbation with matched rescue AND in vivo confirmation", "qualifying_evidence_present": "unclear", "qualifying_evidence_citation": "Bonnet and Dick 1997 [1]; Al-Hajj et al. 2003 [2]", "gamma_hard_rules_triggered": [ "Xenograft tumor-initiation without lineage-resolved endogenous evidence" ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Transplantation sufficiency is positive in selected systems, but the claimed cross-tumour endogenous sufficiency is not tested.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "Endogenous genetic manipulation in autochthonous models", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Chen et al. 2012 [7]; Chan et al. 2026 [14] — both autochthonous. de Sousa e Melo et al. 2017 [8] contributes an orthotopic engineered-mouse result. Mzoughi et al. 2025 [13] is a subcutaneous allograft of engineered tumoroids and is NOT counted as autochthonous (finding RT-04).", "gamma_hard_rules_triggered": [], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Selective cell-state ablation changes tumour growth in native models, with mapped single-state escape.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "Clonal tracking demonstrating persistence of dependency through selection pressure", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Chen et al. 2012 [7]; Shlush et al. 2017 [10]; Cañellas-Socias et al. 2022 [12]", "gamma_hard_rules_triggered": [], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Relapse-specific tracing and ablation demonstrate state-specific causal contributions, with alternative routes and timing boundaries.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC6", "field_valid_perturbation_quote": "Endogenous genetic manipulation in autochthonous models", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Fumagalli et al. 2020 [11]; Cañellas-Socias et al. 2022 [12]; Mzoughi et al. 2025 [13]; Chan et al. 2026 [14]", "gamma_hard_rules_triggered": [], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "The field-valid tests are negative for irreplaceability: cells outside the targeted state replenish equivalent function (de Sousa e Melo 2017; Shimokawa 2017; Fumagalli 2020; Mzoughi 2025), via a regulated dedifferentiation switch (Jiang 2026). Chan 2026 shows non-HPCS cells acquiring the state on orthotopic transplantation and serial allograft; its post-ablation residual cells are attributed by the authors to incomplete recombination, not biological bypass.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Ζ", "requirement_quoted": "Independent causal confirmation across models; reduced viability of major alternatives; relevance beyond one assay class", "satisfied": "partial", "supporting_evidence": [ "Native skin and intestinal lineage tracing show hierarchy, but invasive skin cancer and melanoma do not share one stable architecture." ], "what_would_cross_it": "Independent endogenous lineage and perturbation studies showing the same durable hierarchy across the tumour types claimed." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "At least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse", "satisfied": "no", "supporting_evidence": [ "Selected transplantation assays enrich tumour initiation, but frequency is assay-dependent." ], "what_would_cross_it": "Pre-outcome single-cell fate and ablation evidence showing a consistently rare, exclusive sustaining fraction in native tumours." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Patient-derived system perturbation with matched rescue AND in vivo confirmation", "satisfied": "no", "supporting_evidence": [ "AML and breast serial xenografts demonstrate selected transplantation sufficiency." ], "what_would_cross_it": "Matched patient-derived perturbation, rescue, and in vivo confirmation linked to endogenous lineage behavior across the claimed tumour context." }, { "subclaim_id": "SC4", "threshold": "Ζ", "requirement_quoted": "Independent causal confirmation across models; reduced viability of major alternatives; relevance beyond one assay class", "satisfied": "partial", "supporting_evidence": [ "Endogenous ablation is positive in glioma and lung cancer, but colorectal single-state depletion can be bypassed." ], "what_would_cross_it": "Convergent maintenance ablation and rescue across disease settings within a predeclared stable state definition, without replenishment escape." }, { "subclaim_id": "SC5", "threshold": "Ζ", "requirement_quoted": "Independent causal confirmation across models; reduced viability of major alternatives; relevance beyond one assay class", "satisfied": "partial", "supporting_evidence": [ "Glioma and colorectal residual-state experiments are causal, while LGR5 depletion and human AML tracking show alternative relapse routes." ], "what_would_cross_it": "Independent relapse-specific ablation and rescue across the claimed tumour settings, with human clonal confirmation of the same dependency." }, { "subclaim_id": "SC6", "threshold": "Δ", "requirement_quoted": "A meaningful causal perturbation with a positive result for the proposed mechanism", "satisfied": "no", "supporting_evidence": [ "Multiple direct experiments instead show non-stem-to-stem state replenishment." ], "what_would_cross_it": "Long-term depletion and fate mapping showing that non-stem cells cannot restore equivalent tumour-sustaining function under physiological and treatment pressure." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Permissive melanoma transplantation raises measured tumour-forming frequency and defeats universal rarity.", "Invasive squamous cancers differ from papilloma hierarchy in the same lineage-tracing program.", "Primary colorectal growth, metastatic outgrowth, and surgical recurrence depend on different states and timings.", "Single-state depletion can be bypassed by state conversion in colorectal and lung cancer." ], "note": "Mapped failures of generalization are the reason the context-specific positive result sits at Ε rather than being treated as an untested Δ claim." }, "falsification_patterns_met": [ { "subclaim_id": "SC2", "pattern": "The proposed CSC fraction is not consistently rare under a more permissive assay.", "evidence": "Quintana et al. found tumour-forming capacity in a substantial fraction of unselected melanoma cells under highly permissive xenograft conditions [3,4].", "downgrade_applied": true }, { "subclaim_id": "SC4", "pattern": "The proposed CSC fraction is not universally required for maintenance.", "evidence": "Primary colorectal tumours persisted or regrew after Lgr5-positive-cell depletion [8,9].", "downgrade_applied": true }, { "subclaim_id": "SC5", "pattern": "The proposed marker-defined CSC fraction is not universally required for relapse.", "evidence": "Preoperative Lgr5-positive-cell ablation did not prevent colorectal relapse, whereas EMP1-high residual-cell ablation did [12].", "downgrade_applied": true }, { "subclaim_id": "SC6", "pattern": "Non-CSC populations reacquire equivalent function robustly.", "evidence": "Lgr5-negative colorectal cells and non-high-plasticity lung cells regenerated tumour-sustaining states after dissemination or depletion [11,14].", "downgrade_applied": true }, { "subclaim_id": "SC1", "pattern": "Lineage-resolved evidence contradicts a stable hierarchy in part of the claimed context.", "evidence": "Driessens et al. found invasive squamous cancers compatible with a single equipotent proliferative population [5].", "downgrade_applied": true } ], "pitfalls_flagged": [ { "subclaim_id": "SC2", "pitfall": "Marker identity confused with function", "where": "Marker-enriched transplantation fractions are not assumed to be immutable biological compartments." }, { "subclaim_id": "SC3", "pitfall": "Xenograft capacity equated with endogenous hierarchy", "where": "AML and breast serial transplantation are retained as transplantation sufficiency only." }, { "subclaim_id": "SC5", "pitfall": "Relapse association mistaken for relapse causation", "where": "Human AML relapse tracking is distinguished from direct ablation in glioma and colorectal recurrence models." }, { "subclaim_id": "SC6", "pitfall": "Plasticity ignored", "where": "State replenishment is treated as a direct test of exclusivity." }, { "subclaim_id": "SC1", "pitfall": "Broad generalization across tumour types", "where": "Tumour type and disease stage are explicit context boundaries." } ], "causal_tally_audit": { "tally_claimed_by_document": 0, "tally_after_audit": 9, "items_rejected": [ "Xenograft limiting dilution was not counted as endogenous necessity.", "Serial transplantation was not counted as relapse in the original host.", "Marker enrichment and sphere formation were not counted as independent causal lines.", "Multiple perturbations of the same marker state were not counted as proof of a universal fixed compartment.", "Mzoughi et al. 2025 was reclassified out of the endogenous count: its depletion experiments are subcutaneous allografts of engineered tumoroids in NSG mice (finding RT-04).", "Chan et al. 2026's post-ablation residual high-plasticity cells were not counted as biological bypass, because the authors attribute them to incomplete recombination (finding RT-05).", "Neither added human trial was counted as a decisive perturbation of a prospectively defined rare compartment: neither demonstrated population-selective depletion (finding RT-06)." ], "tally_arithmetic": "The prior edition counted 8. Mzoughi et al. 2025 was reclassified out of the endogenous set (finding RT-04), leaving 7 from the original sources: Driessens 2012, Schepers 2012, Chen 2012, de Sousa e Melo 2017, Fumagalli 2020, Cañellas-Socias 2022, Chan 2026. The two studies added in the red-team pass both carry endogenous genetic perturbations — Jiang 2026 (ZFP36L2 ablation in mouse colon regeneration) and Perelli 2025 (somatic mosaic trace-and-ablate in autochthonous pancreatic cancer) — giving 9. Neither added human trial is counted." }, "steelman": { "case_one_rung_higher": "A Δ or Ε headline is defensible if the question is whether stem-like states causally matter in cancer. They do: native lineage tracing, maintenance ablation in two autochthonous systems, relapse-specific ablation, patient-derived dormancy models and human clonal tracking all support it, and under primary-subclaim aggregation on SC4 the headline would be Ε.", "case_one_rung_lower": "A Β reading would follow if the marker-defined populations were only correlated with outcome. They are not: selective ablation of declared states changes growth, survival and recurrence endpoints in autochthonous glioma, autochthonous lung cancer and a colorectal surgical-recurrence model, which is causal manipulation with disease-relevant endpoints.", "which_rejected": "The higher case is rejected as the headline because the rule prescribed for this hypothesis is scope-matched, the claim is explicitly conjunctive, and the clauses stated across tumour types are the ones that fail; it is retained in the matrix as the Ε-level context-specific result. The lower case is rejected because endogenous causal perturbation with hard endpoints puts the floor decisively above Β.", "blocking_cap_threshold_or_missing_experiment": "To reach Ζ, the nominal claim needs independent endogenous confirmation of the same prospectively defined rare compartment across maintenance and relapse, in more than one tumour type, plus durable exclusion of replenishment and of the major clonal and plastic alternatives. The binding ceilings are the rubric's xenograft hard rule on SC2/SC3 and the negative field-valid perturbation result on SC6." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "High", "confidence_rationale": "The evidence base includes multiple independent endogenous lineage and ablation studies, patient-derived systems, human relapse tracking, two randomized human trials, and direct falsification of fixed-state predictions. Confidence reflects the density and reproducibility of that evidence and the stability of this assessment of it, not confidence that the universal proposition is false. Per hsef-framework.md, (Γ, High) reads: the hypothesis is well studied and we are confident current evidence does not yet justify more than mechanistic plausibility with partial system support.", "rests_on_non_peer_reviewed_work": false, "rationale": "The claim is a six-part conjunction stated across tumour types. The three clauses that carry that cross-tumour scope — rarity (SC2), broad sufficiency (SC3) and irreplaceability (SC6) — all sit at Γ under recorded ceilings: the strongest rarity and serial-reconstitution evidence is transplantation-based and falls under the rubric's xenograft hard rule, and the field-valid endogenous tests of irreplaceability are negative. The three clauses that reach Ε (SC1, SC4, SC5) do so by narrowing to defined tumour contexts, which is what Ε means, so under the prescribed scope-matched rule they are the narrower subclaims reported separately rather than the headline. Stem-like states do causally maintain or reinitiate tumours in defined cancers and stages; that bounded result is reported at Ε in the matrix and is not what the nominal sentence asserts." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": "5", "derivation": "The five-step direction-of-causation procedure was applied in order, stopping at the first match. Step 1 (downstream consequence) does not match: ablating the declared state changes hard endpoints in autochthonous glioma (survival substantially prolonged) and autochthonous lung tumours (burden reduced), so the state is not merely produced by the phenotype. Step 2 (epiphenomenon) does not match: causal dependency is demonstrated, not merely co-occurrence. Step 3 (primary driver) requires all three of prevention on removal, initiation on engagement, and rate limitation; removal does not prevent the phenotype across the claimed scope (primary colorectal tumours persist and regrow after Lgr5+ depletion; preoperative Lgr5+ ablation does not prevent relapse) and rate limitation is not shown generally (a common tumorigenic fraction in permissive melanoma assays; invasive squamous carcinoma compatible with a single equipotent population), so it does not match. Step 4 (permissive factor) does not match: the state is not required, being replenishable, and it does initiate in transplantation. Step 5 matches: the state amplifies, accelerates or maintains a phenotype initiated upstream.", "tournament_used_as_tiebreaker": false, "note": "Derived from direction and necessity, not from competing-model rank. Re-derived independently in the red-team pass and confirmed unchanged (finding RT-13)." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Chan et al. 2026 in-situ lung-cancer lineage/ablation and Mzoughi et al. 2025 single-state versus combined depletion are completed reports, not work currently being run; no named pending experiment addressing the universal rare-fixed-compartment boundary was identified", "justification": "Recent studies directly manipulate dynamic cell states in native tumours and test escape, rather than adding marker associations; because they are completed publications rather than experiments in progress, they support active mechanistic work but not the 'Decisive work underway' value." }, "stability": { "value": "Stable", "trigger": "No named pending result was found that would erase the already observed failures of rarity, stability, and irreplaceability.", "justification": "Additional positive tumour-specific studies may expand the map, but the universal fixed-compartment formulation already has replicated counterexamples." }, "divergence": { "implied_level": "Ζ", "implied_level_basis": "Classic cancer-stem-cell framing in reviews, grant text and press implies Ζ for the nominal claim. The modern dynamic-state literature implies roughly Ε, but for a differently bounded proposition, so the two do not average.", "assessed_level": "Γ", "gap_in_rungs": 2, "value": "Contested", "justification": "Arithmetic if a single implied level is forced: classic framing implies Ζ, assessed Γ, gap +2. Recorded as Contested rather than Substantial overstatement because the field genuinely presents no single implied level — the disagreement is about the proposition itself, fixed rare hierarchy versus dynamic context-dependent state, not about the strength of a shared claim." }, "calibration_note": "M/S/D do not modify the HSEF level or confidence." }, "change_record": { "applies": true, "prior_level": "Ε", "prior_confidence": "High", "prior_source": "D:\\HypothesisCritic\\research\\assessing_the_cancer_stem_cell_hypothesis.md", "derived_before_consulting_prior": true, "new_level": "Γ", "direction": "lowered", "what_moved_it": "Aggregation logic, not new evidence, and no subclaim level changed. The prescribed scope-matched rule sets the overall to the highest subclaim whose scope matches the central claim's scope; the three subclaims that reached Ε did so by narrowing to defined tumour contexts, while the three that carry the claim's stated cross-tumour scope (SC2, SC3, SC6) sit at Γ. The hypothesis-index entry directs that the universal framing be scored in the weakest tumour context claimed. The prior edition reported the Γ reading three times as an alternative while keeping Ε as the headline (finding RT-01).", "divergence_from_other_reviewers": "The earlier prior review classified the mechanism as a primary driver; both this edition and its immediate predecessor derive reinforcing / stabilizing factor because initiation and rate limitation are not established across tumour types and the state can be regenerated. This edition also corrects the predecessor's headline letter, retains its correction of the prior review's inversion of Driessens et al. division rates, and adds human therapeutic evidence that both earlier reviews omitted." }, "proposed_decisive_experiments": [ { "name": "Cross-tumour prospective state-depletion atlas", "experiment": "In predeclared autochthonous models spanning haematologic and solid tumours, prospectively label the proposed apex state, ablate it after tumour establishment, and follow all remaining clones with heritable lineage barcodes through growth and treatment.", "readout": "Tumour maintenance, recurrence-free survival, state-transition trajectories, and restoration of tumour-propagating function.", "critical_control": "Matched ablation of an equally sized non-apex population, ablation-efficiency calibration, and rescue by restoring only the targeted state.", "falsifying_result": "Tumours persist or recur because cells outside the state regenerate equivalent tumour-sustaining function.", "supporting_result": "Across predeclared tumour types, complete apex-state ablation causes durable collapse and no lineage outside the state restores function; matched rescue restores growth." }, { "name": "Human residual-disease lineage and functional linkage", "experiment": "Sample paired primary tumour, minimal residual disease, and relapse before and after therapy; combine phylogenetic lineage reconstruction, state-resolved profiling, and patient-derived selective depletion with matched rescue and in vivo confirmation.", "readout": "Whether relapse founders originate exclusively from the prospectively defined state and remain dependent on it.", "critical_control": "Separate genetic clone identity from reversible transcriptional state and measure sampling sensitivity for rare alternatives.", "falsifying_result": "Relapse founders arise from multiple baseline states or re-enter the proposed state after starting outside it.", "supporting_result": "Independent patients show exclusive state-restricted relapse origins, durable dependence, and rescue-specific restoration." }, { "name": "Rarity-versus-assay calibration", "experiment": "Measure the same prospectively isolated tumour cells by native intravital lineage tracing, orthotopic transplantation, and graded recipient permissiveness without redefining the state after outcomes.", "readout": "The fraction of cells with long-term self-renewal and tumour-reconstitution capacity in each assay.", "critical_control": "Equal viability, cell-cycle state, niche access, barcode recovery, and limiting-dilution uncertainty across fractions.", "falsifying_result": "The estimated rare fraction expands substantially with recipient permissiveness or differs between native and transplantation assays.", "supporting_result": "A consistently rare, prospectively defined fraction carries durable function across native and permissive settings." } ], "knowledge_gaps": [ { "name": "State versus clone", "statement": "For many human tumours, it remains unresolved whether tumour-sustaining capacity tracks a genetically stable clone, a reversible transcriptional state, or both.", "relevance": "This determines whether selective targeting can be durable or is bypassed by state transition." }, { "name": "Ablation completeness and escape", "statement": "Residual growth can reflect biological replenishment, incomplete depletion, or transgene-silent escape, and these mechanisms are not always separable.", "relevance": "Necessity cannot be inferred without distinguishing target escape from genuine dispensability." }, { "name": "Human relapse causality", "statement": "Human phylogenetic studies identify relapse origins, but direct state-specific necessity and rescue are largely established in models rather than patients.", "relevance": "This is the main boundary between disease-relevant model causality and broad human relapse claims." }, { "name": "Durability after multi-state targeting", "statement": "Recent combined-state depletion can regress tumours during treatment, but durable control after withdrawal and across genotypes is not established.", "relevance": "Durable failure of replenishment is required for the irreplaceable-apex claim." } ], "review_metadata": { "review_date": "2026-09-30", "reviewer": "OpenAI Codex using HSEF v5.4 (authoring); Claude (Anthropic) cross-model red team and synthesis", "evidence_base_note": "Primary literature through 2026-09-30; accessible full text read where available. The prior review was withheld until the independent score was locked. The red-team pass resolved every identifier, re-verified every numeric claim, and searched 2023-2026 for missed evidence, adding two randomized human trials and two dedifferentiation studies.", "literature_tools_available": true, "literature_tools_note": "Direct PubMed, PubMed Central, Europe PMC, and accessible primary PDFs were used. Scite was unavailable by user report, so citation-context counts are treated as unavailable rather than zero.", "skill_version": "5.4", "validator_run": "pass", "validator_warnings_addressed": "All load-bearing claims are registered; source depth and status flags are explicit; aggregation alternatives, scope, caps, upper-ladder equivalents, rubric-routing check and the five-step role derivation are recorded.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": false, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "No sealed calibration target was supplied.", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Standalone evidence review. The new score was locked before the prior cancer-stem-cell review was opened, but no independently authored sealed expected band existed." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "germline_or_somatic_genetic_natural_experiment", "available": true, "why_not_sufficient": "Human clonal evolution and relapse phylogenies show cellular origins but do not establish a universally rare, fixed, irreplaceable state." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "There is no comparable cross-population dose-response relating a prospectively defined CSC fraction to necessity across tumour types." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "Single-state withdrawal and regrowth experiments often demonstrate replenishment, supporting the dynamic alternative rather than the fixed nominal claim." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "Human randomized evidence now exists in both directions and neither arm carries the claim. CanStem303C, phase III in previously treated metastatic colorectal cancer (n=1,253), found no overall-survival benefit from adding napabucasin to FOLFIRI (14.3 vs 13.8 months, HR 0.976, one-sided P=.74; pSTAT3-positive 13.2 vs 12.1 months, HR 0.969, one-sided P>.99), but napabucasin's status as a CSC-directed agent is contested. A randomized phase II of glasdegib plus low-dose cytarabine in AML/high-risk MDS (n=88 vs 44) improved survival (8.8 vs 4.9 months, HR 0.51, 80% CI 0.39-0.67, P=0.0004), but Hedgehog inhibition is pleiotropic and the trial shows no population-selective killing. No human trial has demonstrated depletion of a prospectively defined rare compartment and measured recurrence against it (finding RT-06). In mice, dependencies differ by tumour type and stage." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 19, "claims_total": 17, "claims_verified": 17, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 19, "generated_by": "OpenAI Codex with HSEF v5.4 (original); red-team synthesis by Claude (Anthropic) 2026-09-30; validator 2.4", "gate_passed": true }, "claims": [ { "id": "C1", "text": "A primitive human AML fraction initiated xenograft leukaemia and reproduced phenotypic hierarchy, supporting a functional hierarchy in that transplantation system.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Primary abstract and metadata", "verified_on": "2026-09-27", "note": "Transplantation scope retained." }, { "id": "C2", "text": "In human breast cancer, tumorigenic cells were prospectively isolated as CD44-positive, CD24-negative/low, Lineage-negative in eight of nine patients; as few as 100 such cells formed tumours in mice whereas tens of thousands of cells with alternate phenotypes did not, and the population could be serially passaged.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Complete primary full text", "verified_on": "2026-09-27", "note": "The numeric contrast is experiment-specific, not a universal frequency.", "verification_note": "Abstract-verified. The prior edition reported 200 versus 20,000 cells at full-text depth; no accessible record substantiates those figures (PMC full text empty, Europe PMC fullTextXML HTTP 500, publisher 403), so the abstract's values are used (finding RT-03)." }, { "id": "C3", "text": "Under permissive melanoma xenograft conditions, approximately 25% of unselected cells formed tumours in limiting dilution across 12 patients, and in a separate single-cell series across four patients 69 of 254 injections (27%, range 12-65% per patient) formed tumours; a follow-up study found 28% of single cells tumorigenic and none of 22 markers enriching tumorigenic cells.", "carries_number": true, "load_bearing_for": [ "SC2", "SC6" ], "source_ns": [ 3, 4 ], "verification": "verified", "verified_against": "Complete primary full texts", "verified_on": "2026-09-27", "note": "The result tests assay-dependent rarity, not native human equipotence." }, { "id": "C4", "text": "In mouse skin papilloma, the stem-cell-like population accounted for about 20% of labelled proliferative tumour cells and divided about twice per day, approximately four times the progenitor rate in the same tumour (implying roughly 0.5 divisions per day for progenitors); invasive squamous carcinoma was equally consistent with a single equipotent proliferative population.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Complete primary PDF", "verified_on": "2026-09-27", "note": "Corrects the division-rate inversion in the prior review." }, { "id": "C5", "text": "Lgr5-positive cells comprised approximately 5-10% of cells in mouse intestinal adenomas and generated long-lived multilineage clones in native tumours.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary PDF", "verified_on": "2026-09-27", "note": "Lineage evidence, not ablation." }, { "id": "C6", "text": "In an endogenous mouse glioma model, quiescent Nestin-expressing cells regenerated tumour after temozolomide, and genetic ablation impaired growth and prolonged survival, with transgene-silent escape limiting interpretation.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Complete primary full text", "verified_on": "2026-09-27", "note": "Direct maintenance and recurrence evidence with an explicit escape boundary." }, { "id": "C7", "text": "Lgr5-positive-cell ablation restricted primary colorectal growth without durable regression, and Lgr5-negative or differentiated cells regenerated Lgr5-positive tumour-propagating cells; metastatic dependence differed from primary-tumour dependence.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5", "SC6" ], "source_ns": [ 8, 9 ], "verification": "verified", "verified_against": "Primary abstracts and publisher summaries", "verified_on": "2026-09-27", "note": "No abstract-external effect size used." }, { "id": "C8", "text": "Paired human AML samples support at least two relapse patterns: one arising from rare stem/progenitor cells and another from larger committed populations carrying stemness programs.", "carries_number": false, "load_bearing_for": [ "SC5", "SC6" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Primary abstract and metadata", "verified_on": "2026-09-27", "note": "Human lineage evidence, not an ablation test." }, { "id": "C9", "text": "Lgr5-negative colorectal cells can seed metastases and then acquire Lgr5 expression; the acquired Lgr5 state supports long-term metastatic outgrowth.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5", "SC6" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Complete primary full text", "verified_on": "2026-09-27", "note": "Separates seeding from outgrowth." }, { "id": "C10", "text": "In a colorectal surgical-recurrence model, preoperative EMP1-high residual-cell ablation prevented most relapses, whereas preoperative Lgr5-positive-cell ablation did not; isolated populations could re-establish tumour states.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5", "SC6" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Complete primary full text and methods", "verified_on": "2026-09-27", "note": "Stage-specific causal contrast." }, { "id": "C11", "text": "In WNT-dependent colorectal cancer tumoroids transplanted subcutaneously into immunodeficient mice, sustained depletion of either the LGR5-positive or the oncofetal state alone failed to maintain tumour stasis indefinitely, while co-targeting both states caused tumour shrinkage and significantly delayed resurgence.", "carries_number": false, "load_bearing_for": [ "SC4", "SC6" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Complete primary full text and methods", "verified_on": "2026-09-27", "note": "Supports state redundancy, not a single fixed apex." }, { "id": "C12", "text": "In autochthonous mouse lung cancer, a high-plasticity cell state causally supported progression, maintenance and therapy resistance, and its ablation reduced tumour burden; non-high-plasticity cells acquired the state after orthotopic transplantation and in serial allografts, while residual high-plasticity cells after in-situ ablation were attributed by the authors to incomplete recombination.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4", "SC5", "SC6" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Complete primary full text and methods", "verified_on": "2026-09-27", "note": "Recent decisive dynamic-state evidence." }, { "id": "C13", "text": "Dormant LGR5-positive cells persisted through chemotherapy in human colorectal organoid xenografts, and COL17A1 disruption reduced the dormant fraction and increased treatment sensitivity.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Primary abstract and metadata", "verified_on": "2026-09-27", "note": "Treatment-stage xenograft evidence." }, { "id": "C14", "text": "In the randomized phase III CanStem303C trial in previously treated metastatic colorectal cancer, adding napabucasin to FOLFIRI did not improve overall survival: 14.3 versus 13.8 months (n=624 vs 629), hazard ratio 0.976, one-sided P=.74; in the pSTAT3-positive population (n=275 vs 272) 13.2 versus 12.1 months, hazard ratio 0.969, one-sided P>.99.", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 16 ], "verification": "verified", "added_by": "red-team synthesis 2026-09-30" }, { "id": "C15", "text": "In a randomized phase II trial in newly diagnosed AML or high-risk MDS unsuitable for intensive chemotherapy, glasdegib plus low-dose cytarabine (n=88) gave median overall survival of 8.8 months (80% CI 6.9-9.9) versus 4.9 months (3.5-6.0) for low-dose cytarabine alone (n=44), hazard ratio 0.51 (80% CI 0.39-0.67, P=0.0004), with complete remission in 17.0% versus 2.3%.", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 17 ], "verification": "verified", "added_by": "red-team synthesis 2026-09-30" }, { "id": "C16", "text": "ZFP36L2, mutated in 5-10% of colorectal cancers, is a stress-responsive switch for dynamic dedifferentiation: its ablation in mouse colon regeneration models inhibited dedifferentiation and intestinal-stem-cell function, and loss of its function in human colorectal cancer abrogated metastatic seeding and outgrowth of LGR5-positive canonical metastases while promoting non-canonical lineage plasticity.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 18 ], "verification": "verified", "added_by": "red-team synthesis 2026-09-30" }, { "id": "C17", "text": "Somatic mosaic genome engineering was used to trace and ablate malignant mesenchymal lineages along the epithelial-to-mesenchymal continuum in pancreatic cancer; ablation of clones capable of mesenchymal plasticity abolished the associated mutational processes and evolutionary patterns, supporting cell-state-restricted patterns of evolution.", "carries_number": false, "load_bearing_for": [ "SC1", "SC6" ], "source_ns": [ 19 ], "verification": "verified", "added_by": "red-team synthesis 2026-09-30" } ], "citation_ledger": [ { "n": 1, "citation": "Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.", "tier": "A", "kind": "primary", "pmid": "9212098", "doi": "10.1038/nm0797-730", "url": "https://pubmed.ncbi.nlm.nih.gov/9212098/", "status_flags": [ "none_found" ], "carries_claims": [ "C1" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "bonnet-dick-aml-1997", "access_depth": "abstract_metadata", "access_note": "PubMed and Europe PMC metadata and abstract read; full text was not available through the checked routes." }, { "n": 2, "citation": "Al-Hajj M et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-3988.", "tier": "A", "kind": "primary", "pmid": "12629218", "doi": "10.1073/pnas.0530291100", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC153034/", "status_flags": [ "author correction: DOI 10.1073/pnas.1131491100; omitted financial-interest acknowledgement" ], "carries_claims": [ "C2" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "al-hajj-breast-2003", "access_depth": "abstract_metadata", "access_note": "PMC full text unavailable through the PMC API, Europe PMC fullTextXML returned HTTP 500, publisher returned 403; assessed at abstract/metadata depth (finding RT-03)." }, { "n": 3, "citation": "Quintana E et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593-598.", "tier": "A", "kind": "primary", "pmid": "19052619", "doi": "10.1038/nature07567", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2597380/", "status_flags": [ "none_found" ], "carries_claims": [ "C3" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "quintana-melanoma-2008", "access_depth": "full_text_complete", "access_note": "Complete PMC full text read." }, { "n": 4, "citation": "Quintana E et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010;18:510-523.", "tier": "A", "kind": "primary", "pmid": "21075313", "doi": "10.1016/j.ccr.2010.10.012", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3031091/", "status_flags": [ "none_found" ], "carries_claims": [ "C3" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "quintana-melanoma-2010", "access_depth": "full_text_complete", "access_note": "Complete PMC full text read." }, { "n": 5, "citation": "Driessens G et al. Defining the mode of tumour growth by clonal analysis. Nature. 2012;488:527-530.", "tier": "A", "kind": "primary", "pmid": "22854777", "doi": "10.1038/nature11344", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5553110/", "status_flags": [ "none_found" ], "carries_claims": [ "C4" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "driessens-skin-2012", "access_depth": "full_text_complete", "access_note": "Complete primary PDF read, including methods, model parameters, and supplementary interpretation." }, { "n": 6, "citation": "Schepers AG et al. Lineage tracing reveals Lgr5-positive stem cell activity in mouse intestinal adenomas. Science. 2012;337:730-735.", "tier": "A", "kind": "primary", "pmid": "22855427", "doi": "10.1126/science.1224676", "url": "https://pubmed.ncbi.nlm.nih.gov/22855427/", "status_flags": [ "none_found" ], "carries_claims": [ "C5" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "schepers-adenoma-2012", "access_depth": "full_text_complete", "access_note": "Complete primary PDF read." }, { "n": 7, "citation": "Chen J et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522-526.", "tier": "A", "kind": "primary", "pmid": "22854781", "doi": "10.1038/nature11287", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3427400/", "status_flags": [ "none_found" ], "carries_claims": [ "C6" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "chen-glioma-2012", "access_depth": "full_text_complete", "access_note": "Complete PMC full text read." }, { "n": 8, "citation": "de Sousa e Melo F et al. A distinct role for Lgr5-positive stem cells in primary and metastatic colon cancer. Nature. 2017;543:676-680.", "tier": "A", "kind": "primary", "pmid": "28358093", "doi": "10.1038/nature21713", "url": "https://pubmed.ncbi.nlm.nih.gov/28358093/", "status_flags": [ "none_found" ], "carries_claims": [ "C7" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "de-sousa-crc-2017", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and metadata read; no abstract-external effect size used." }, { "n": 9, "citation": "Shimokawa M et al. Visualization and targeting of LGR5-positive human colon cancer stem cells. Nature. 2017;545:187-192.", "tier": "A", "kind": "primary", "pmid": "28355176", "doi": "10.1038/nature22081", "url": "https://pubmed.ncbi.nlm.nih.gov/28355176/", "status_flags": [ "none_found" ], "carries_claims": [ "C7" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "shimokawa-crc-2017", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, metadata, and accessible Nature summary read; no abstract-external effect size used." }, { "n": 10, "citation": "Shlush LI et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547:104-108.", "tier": "A", "kind": "primary", "pmid": "28658204", "doi": "10.1038/nature22993", "url": "https://pubmed.ncbi.nlm.nih.gov/28658204/", "status_flags": [ "none_found" ], "carries_claims": [ "C8" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "shlush-aml-relapse-2017", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and metadata read; no abstract-external effect size used." }, { "n": 11, "citation": "Fumagalli A et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell. 2020;26:569-578.e7.", "tier": "A", "kind": "primary", "pmid": "32169167", "doi": "10.1016/j.stem.2020.02.008", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7118369/", "status_flags": [ "none_found" ], "carries_claims": [ "C9" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "fumagalli-crc-2020", "access_depth": "full_text_complete", "access_note": "Complete PMC full text and methods read." }, { "n": 12, "citation": "Cañellas-Socias A et al. Metastatic recurrence in colorectal cancer arises from residual EMP1-positive cells. Nature. 2022;611:603-613.", "tier": "A", "kind": "primary", "pmid": "36352230", "doi": "10.1038/s41586-022-05402-9", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7616986/", "status_flags": [ "none_found" ], "carries_claims": [ "C10" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "canellas-crc-relapse-2022", "access_depth": "full_text_complete", "access_note": "Complete PMC full text and methods read." }, { "n": 13, "citation": "Mzoughi S et al. Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Nat Genet. 2025;57:402-412.", "tier": "A", "kind": "primary", "pmid": "39930084", "doi": "10.1038/s41588-024-02058-1", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11821538/", "status_flags": [ "none_found" ], "carries_claims": [ "C11" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "mzoughi-crc-2025", "access_depth": "full_text_complete", "access_note": "Complete PMC full text and methods read." }, { "n": 14, "citation": "Chan JE et al. Critical role for a high-plasticity cell state in lung cancer. Nature. 2026;650:231-241.", "tier": "A", "kind": "primary", "pmid": "41565826", "doi": "10.1038/s41586-025-09985-x", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12960256/", "status_flags": [ "none_found" ], "carries_claims": [ "C12" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "chan-lung-hpcs-2026", "access_depth": "full_text_complete", "access_note": "Complete PMC full text and methods read." }, { "n": 15, "citation": "Ohta Y et al. Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022;608:784-794.", "tier": "A", "kind": "primary", "pmid": "35798028", "doi": "10.1038/s41586-022-05043-y", "url": "https://pubmed.ncbi.nlm.nih.gov/35798028/", "status_flags": [ "none_found" ], "carries_claims": [ "C13" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "ohta-crc-dormancy-2022", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and metadata read; no abstract-external effect size used." }, { "n": 16, "citation": "Shah MA, Yoshino T, Tebbutt NC, et al. Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study. Clin Colorectal Cancer. 2023;22:100-110.", "tier": "A", "kind": "primary", "pmid": "36503738", "doi": "10.1016/j.clcc.2022.11.002", "url": "https://pubmed.ncbi.nlm.nih.gov/36503738/", "opened": true, "access_depth": "abstract_metadata", "status_flags": [ "none_found" ], "status_checked_on": "2026-09-30", "carries_claims": [ "C14" ], "added_by": "red-team synthesis 2026-09-30" }, { "n": 17, "citation": "Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379-389.", "tier": "A", "kind": "primary", "pmid": "30555165", "doi": "10.1038/s41375-018-0312-9", "url": "https://pubmed.ncbi.nlm.nih.gov/30555165/", "opened": true, "access_depth": "abstract_metadata", "status_flags": [ "none_found" ], "status_checked_on": "2026-09-30", "carries_claims": [ "C15" ], "added_by": "red-team synthesis 2026-09-30" }, { "n": 18, "citation": "Jiang Q, Raghavan MS, Rodriguez AM, et al. ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer. Nature. 2026;657:1053-1063.", "tier": "A", "kind": "primary", "pmid": "42557330", "doi": "10.1038/s41586-026-10890-0", "url": "https://pubmed.ncbi.nlm.nih.gov/42557330/", "opened": true, "access_depth": "abstract_metadata", "status_flags": [ "none_found" ], "status_checked_on": "2026-09-30", "carries_claims": [ "C16" ], "added_by": "red-team synthesis 2026-09-30" }, { "n": 19, "citation": "Perelli L, Zhang L, Mangiameli S, et al. Evolutionary fingerprints of epithelial-to-mesenchymal transition. Nature. 2025;640:1083-1092.", "tier": "A", "kind": "primary", "pmid": "40044861", "doi": "10.1038/s41586-025-08671-2", "url": "https://pubmed.ncbi.nlm.nih.gov/40044861/", "opened": true, "access_depth": "abstract_metadata", "status_flags": [ "none_found" ], "status_checked_on": "2026-09-30", "carries_claims": [ "C17" ], "added_by": "red-team synthesis 2026-09-30" } ], "independence_basis": { "required": true, "lines": [ { "label": "Native lineage architecture", "sources": [ 5, 6 ], "excludes_error": "Rules out the possibility that every observed hierarchy is created only by xenograft recipient selection or ectopic niche failure." }, { "label": "Endogenous cell-state ablation and recurrence intervention", "sources": [ 7, 12, 14 ], "excludes_error": "Rules out a purely descriptive lineage association by directly changing maintenance or relapse endpoints." }, { "label": "Patient-derived and human relapse-origin evidence", "sources": [ 9, 10, 15 ], "excludes_error": "Reduces the chance that the entire architecture is peculiar to engineered mouse cancers, while retaining xenograft and observational limitations explicitly." }, { "label": "State-replenishment and multi-state depletion", "sources": [ 11, 13, 14 ], "excludes_error": "Rules out interpreting persistence after single-state targeting solely as failed target engagement; lineage conversion and combined depletion directly test bypass." } ], "shared_failure_mode_checked": true, "note": "These independent lines justify Ζ for the bounded dynamic-hierarchy alternative, not for the original rare fixed universal proposition. No single xenograft, marker, or engineered-lineage artifact explains all four lines." }, "redteam_synthesis": { "date": "2026-09-30", "red_team_model": "Claude (Anthropic), cross-model red team; authoring model(s) differed", "inputs": [ "cancer-stem-cell-hierarchy-hsef-v54-review.md", "cancer-stem-cell-hierarchy-hsef-v54-scorecard.json", "cancer-stem-cell-hierarchy-hsef-v54-validation.txt", "README-cancer-stem-cell-hsef-v54.txt" ], "mode": "single-version red team", "findings_total": 16, "findings_accepted": 12, "findings_rejected": 4, "score_before": { "level": "Ε", "confidence": "High", "role": "reinforcing / stabilizing factor" }, "score_after": { "level": "Γ", "confidence": "High", "role": "reinforcing / stabilizing factor" }, "grade_changed": true, "grade_change_rationale": "Scope-matched aggregation, the rule prescribed by the hypothesis index for this entry, was misapplied. The rule sets the overall level to the highest subclaim whose scope matches the central claim's scope; the three subclaims that reached Ε reached it only by narrowing to defined tumour contexts, which is what Ε denotes, while the three subclaims that carry the claim's stated cross-tumour scope (SC2 rarity, SC3 sufficiency, SC6 irreplaceability) all sit at Γ under recorded ceilings. The index's own rationale directs that the universal framing be scored in the weakest tumour context claimed. Correctly applied, scope-matched and weakest-link both return Γ; only primary-subclaim aggregation, which was not prescribed, returns Ε. No subclaim level changed and no evidence was rescored. The input review already reported Γ three times as an alternative reading.", "citations_checked": 19, "citations_corrected": 1, "citations_removed": 0, "citations_added": 4, "confabulated_identifiers_found": 0, "audit_trail": "redteam/REDTEAM_REPORT.md; redteam/SYNTHESIS_CHANGE_LOG.md" }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "High", "confidence_rationale": "The evidence base includes multiple independent endogenous lineage and ablation studies, patient-derived systems, human relapse tracking, two randomized human trials, and direct falsification of fixed-state predictions. Confidence reflects the density and reproducibility of that evidence and the stability of this assessment of it, not confidence that the universal proposition is false. Per hsef-framework.md, (Γ, High) reads: the hypothesis is well studied and we are confident current evidence does not yet justify more than mechanistic plausibility with partial system support.", "rests_on_non_peer_reviewed_work": false, "rationale": "The claim is a six-part conjunction stated across tumour types. The three clauses that carry that cross-tumour scope — rarity (SC2), broad sufficiency (SC3) and irreplaceability (SC6) — all sit at Γ under recorded ceilings: the strongest rarity and serial-reconstitution evidence is transplantation-based and falls under the rubric's xenograft hard rule, and the field-valid endogenous tests of irreplaceability are negative. The three clauses that reach Ε (SC1, SC4, SC5) do so by narrowing to defined tumour contexts, which is what Ε means, so under the prescribed scope-matched rule they are the narrower subclaims reported separately rather than the headline. Stem-like states do causally maintain or reinitiate tumours in defined cancers and stages; that bounded result is reported at Ε in the matrix and is not what the nominal sentence asserts." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "High", "confidence_rationale": "The evidence base includes multiple independent endogenous lineage and ablation studies, patient-derived systems, human relapse tracking, two randomized human trials, and direct falsification of fixed-state predictions. Confidence reflects the density and reproducibility of that evidence and the stability of this assessment of it, not confidence that the universal proposition is false. Per hsef-framework.md, (Γ, High) reads: the hypothesis is well studied and we are confident current evidence does not yet justify more than mechanistic plausibility with partial system support.", "rests_on_non_peer_reviewed_work": false, "rationale": "The claim is a six-part conjunction stated across tumour types. The three clauses that carry that cross-tumour scope — rarity (SC2), broad sufficiency (SC3) and irreplaceability (SC6) — all sit at Γ under recorded ceilings: the strongest rarity and serial-reconstitution evidence is transplantation-based and falls under the rubric's xenograft hard rule, and the field-valid endogenous tests of irreplaceability are negative. The three clauses that reach Ε (SC1, SC4, SC5) do so by narrowing to defined tumour contexts, which is what Ε means, so under the prescribed scope-matched rule they are the narrower subclaims reported separately rather than the headline. Stem-like states do causally maintain or reinitiate tumours in defined cancers and stages; that bounded result is reported at Ε in the matrix and is not what the nominal sentence asserts." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\cancer-stem-cell\\consensus-browser-links.json", "sha256": "0d0555b65f7e7d373e42f2359c9cbf3a3b5688dcde27784c0b702cb86ccd892b" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\cancer-stem-cell\\consensus-browser.txt", "sha256": "e3ca63985dbd1c6350c71a7d266f83942cf8ef2281af921a53cddd45f2b55f97" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\cancer-stem-cell\\consensus-pro-links.json", "sha256": "824765ea93e60475fa65f94c6ed78876de705ed7e11c8611949a0e64bd033fcf" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\cancer-stem-cell\\consensus-pro.txt", "sha256": "b6db7b616360bbb621979f4d01a7d6bbd6d082bb1394fd0e0f0c25aa076e2951" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\cancer-stem-cell\\consensus-targeted-check.txt", "sha256": "5047b178d377610e8a2b719a6c06f9e3a340f56703f924261920bba806d59612" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record.", "existing_primary_reconciliation": { "slug": "cancer-stem-cell", "consensus_used": true, "rawproof": [ "deliverables/prepublication-enrichment-2026-10-05/website-series/cancer-stem-cell/consensus-browser.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/cancer-stem-cell/consensus-targeted-check.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/cancer-stem-cell/consensus-browser-links.json" ], "reconciliation_existing": "Yes, with explicit rejection of later reviews as primary proof; 11 primary identifiers in timeline; selected single-cell/Methods passage checked.", "primary_sources_matched": [ "9212098", "12629218", "19052619", "22854781", "22855427", "28355176", "28358093", "32169167", "36352230", "41565826", "42557330" ], "limitations": "Consensus paper links alone do not establish body access. Dated addendum describes one selected passage, not complete paper checks." } } }